Olgram

Olgram is developing a groundbreaking patented molecule to cure immune deficiency post traumatic brain injury (TBI). This unique molecule is designed to address TBI through an original target and novel mechanism of action. Proven in validated in vivo proof-of-concept studies, it has the potential to cure immunodepression following traumatic brain injury, a condition affecting 7 million patients annually across the USA and EU.

In addition to therapeutic advancements, Olgram has identified a biomarker through the inclusion of 170 patients in studies, which acts as a companion diagnostic. This innovation enables prediction of which patients are most likely to develop immunodepression following various types of traumas, enhancing therapeutic approaches and patient outcomes.

Investment and Growth Opportunity

Olgram is completing a series A funding round of €9 million, with €4 million already secured. This investment will propel the company to a significant value inflection point—the completion of phase 1 clinical trial (First-In-Man study) of the lead program slated for 2027. Over the next 6 years, Olgram anticipates a total funding need of €40 million to achieve objectives and milestones, providing a point of exit for investors (after completion of phase 2 in 2031).

A Robust Team of Experienced Managers

Olgram is led by a team of leaders and visionaries in the biotechnology industry, each bringing a wealth of experience and a proven track record of success. The management combines strategic, operational, and scientific expertise to position Olgram at the forefront of biotechnology innovation.

• Maryvonne Hiance, Chairwoman and co-founder: A formidable entrepreneur in the biotechnology space, Maryvonne has established and successfully exited 2 biotechnology companies (sold over 600millions), including one high-profile IPO (Ose immunotherapeutics)
• Pierre Rocheteau, CEO and co-founder: With a solid decade of industry experience as the CEO of a 900+ people blue biotechnology company, Pierre brings a deep understanding of biotech market dynamics and operational excellence.
• Alexander Kettner, CSO: Boasts 15 years of dedicated service in immunology (UNIL, Harvard) and drug development (Anergis), with an impressive track record from lead optimization through to Phase 2 clinical trials.